Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-338-8 | CAS number: 791-28-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 974
- Report date:
- 1974
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Triphenylphosphine oxide
- EC Number:
- 212-338-8
- EC Name:
- Triphenylphosphine oxide
- Cas Number:
- 791-28-6
- Molecular formula:
- C18H15OP
- IUPAC Name:
- (diphenylphosphoroso)benzene
- Test material form:
- solid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Gassner
- Weight at study initiation: males: 222 (170 - 252) g; females: 176 (153 - 188) g
ENVIRONMENTAL CONDITIONS
not reported
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 2 - 30 % aqueous suspension with carboxymethyl cellulose and 2 - 3 drops of Cremophor EL.
MAXIMUM DOSE VOLUME APPLIED: 21.4 mL/kg bw - Doses:
- 6400; 3200; 1600; 800; 400; 320; 200 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Frequency of observations and weighing: Body weight was measured on the application day, on day 3 and 4, respectively, and on day 7. Observation of clinical signs was several times on the day of administration and once daily afterwards with the exception of weekends and on holidays.
- Necropsy of survivors performed: yes - Statistics:
- Calculation of LD50 by method of Litchfield and Wilcoxon.
Results and discussion
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 685 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 486 - <= 966
- Remarks on result:
- other: mortality was observed in doses of 320 mg/kg bw and higher
- Mortality:
- see table "any other information on results incl. tables"
- Clinical signs:
- other: Convulsions, dyspnea, apathy, tremors, salivation, eye discharge, partial exophthalmus, ventral or lateral body position, staggering, exsiccosis, paresis of hind limbs. 6400 and 3200 mg/kg bw: 15 minutes after application convulsions, dyspnea, cower posi
- Gross pathology:
- Hyperemia, dilatation of heart and gastroesophageal vestibule, fine ulcerations, diarrhoeic intestinal content, discoloration of kidneys and liver in animals that died.
Nothing abnormal found in sacrificed animals.
Any other information on results incl. tables
Mortality
Dose [mg/kg bw] |
Concentration in vehicle [%] |
Number of animals and sex |
1 h |
24 h |
48 h |
7 d |
6400 |
30 |
5 M |
0/5 |
5/5 |
5/5 |
5/5 |
|
|
5 F |
0/5 |
5/5 |
5/5 |
5/5 |
3200 |
30 |
5 M |
0/5 |
4/5 |
5/5 |
5/5 |
|
|
5 F |
0/5 |
3/5 |
4/5 |
5/5 |
1600 |
16 |
5 M |
0/5 |
2/5 |
2/5 |
5/5 |
|
|
5 F |
0/5 |
5/5 |
5/5 |
5/5 |
800 |
8 |
5 M |
0/5 |
1/5 |
1/5 |
2/5 |
|
|
5 F |
0/5 |
2/5 |
4/5 |
4/5 |
400 |
4 |
5 M |
0/5 |
0/5 |
0/5 |
0/5 |
|
|
5 F |
0/5 |
0/5 |
1/5 |
2/5 |
320 |
4 |
5 M |
0/5 |
0/5 |
0/5 |
0/5 |
|
|
5 F |
0/5 |
0/5 |
1/5 |
1/5 |
200 |
2 |
5 M |
0/5 |
0/5 |
0/5 |
0/5 |
|
|
5 F |
0/5 |
0/5 |
0/5 |
0/5 |
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- In a study comparable to OECD Guideline 401, the LD50 of the test item was determined to be 685 (95 % CL: 486 - 966) mg/kg bw.
- Executive summary:
The acute oral toxicity of the test item was assessed in a study comparable to OECD Guideline 401 (Acute Oral Toxicity, standard acute method). Male and female rats of the Sprague-Dawley strain (weight at study initiation: males: 222 (170 - 252) g; females: 176 (153 - 188) g; number of animals per sex per dose: 5) were exposed by gavage to doses of 6400; 3200; 1600; 800; 400; 320; 200 mg test item/kg bw over a test duration of 7 days. As vehicle carboxymethyl cellulose (2 - 30 % aqueous suspension with carboxymethyl cellulose and 2 - 3 drops of Cremophor EL) was used. No control was performed. Body weight was measured on the application day, on day 3 and 4, respectively, and on day 7. Observation of clinical signs was performed several times on the day of administration and once daily afterwards with the exception of weekends and on holidays. In addition, necropsy of survivors was conducted. The LD50 was calculated by method of Litchfield and Wilcoxon.The following clinical signs were observed: Convulsions, dyspnea, apathy, tremors, salivation, eye discharge, partial exophthalmus, ventral or lateral body position, staggering, exsiccosis, paresis of hind limbs. At 6400 and 3200 mg/kg bw, 15 minutes after application convulsions, dyspnea and cower position occurred. Hours later apathy, tremors, cower position, at 6400 mg/kg bw additionally gasping for breath and partial exophtalmus was observed. During observation period lateral position, dyspnea, apathy, partially secretion out of eyes and mouth and cower position was noted. For level of 1600 mg/kg bw, dyspnea, cower position, apathy, lateral body position, staggering and clonic convulsions was reported. The symptoms were stable for the following days (additionally tremors and secretion out of mouth and eyes). At 800 - 320 mg/kg bw, staggering, partially cower position and creeping, at 800 and 400 mg/kg bw additionally convulsions, latero-abdominal position, dyspnea, aggressiveness, partially weakness of hind limbs, biting convulsions, partially tremors and salivation was observed. During the following days all symptoms ameliorated; at 800 mg/kg additionally exsiccosis occurred. Animals were free of symptoms around day 4. At 200 mg/kg bw, hours after application animals were in cower position and slightly apathic. Animals were free of symptoms on day 2. The body weight gain stagnated during observation period in survivors of all dose groups. By gross pathology, hyperemia, dilatation of heart and gastroesophageal vestibule, fine ulcerations, diarrhoeic intestinal content, discoloration of kidneys and liver in animals that died was detected. Nothing abnormal was found in sacrificed animals. Mortality was observed in doses of 320 mg/kg bw and higher. In result, the LD50 of the test item was determined to be 685 (95 % CL: 486 - 966) mg/kg bw. Based on this result, the test item is considered to be classified as category 4 based on GHS criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.